Advanced renal cell carcinoma treatment

Dr. Scot Ebbinghaus from Merck Research Laboratories discusses Merck’s KEYTRUDA with Inlyta as first-line treatment for advanced renal cell carcinoma.

Dr. Scot Ebbinghaus joined Merck Research Labs Late Stage Oncology Development in 2007. He is currently Vice President and Therapeutic Area Head for Late Stage Oncology Development with responsibilities for overseeing the Keytruda (pembrolizumab) development program as well as responsibility for the development of Lynparza (olaparib) and selumetinib in collaboration with Astra Zeneca.

Prior to joining Merck, Dr. Ebbinghaus was an Associate Professor at the University of Arizona in the Department of Medicine, Section of Hematology/Oncology.

Dr. Ebbinghaus earned his M.D. degree from the University of Missouri-Kansas City, completed his residency in Internal Medicine and his fellowship in Hematology-Oncology at the University of Alabama-Birmingham. Dr. Ebbinghaus has published over 40 manuscripts and 5 book chapters in the field of Oncology. In addition to his current responsibilities at Merck, Dr. Ebbinghaus is an attending physician at Fox Chase Cancer Center in Philadelphia in the Thoracic Oncology unit.

Liked it? Take a second to support healthprofessionalradio on Patreon!


Leave a Reply

You must be logged in to post a comment.